Elkfork Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Elkfork Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-272	Closed	-$24K	–	1051
2019 Q1	$24K	Buy	+272	New	+$25.2K	﹤0.01%	1012

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Elkfork Partners's BMRN Position: Q2 2019 in Review

Elkfork Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 272 shares — an estimated $24K sold.

Elkfork Partners first reported a position in BMRN in Q1 2019 and held it in 1 quarter. The position peaked at $24K in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Elkfork Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Elkfork Partners sold 272 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $24K.
Elkfork Partners first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 1 quarter.
Elkfork Partners's BioMarin Pharmaceuticals position peaked at $24K in Q1 2019.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Elkfork Partners's 13F filing for Q2 2019, filed 13 Aug 2019.